AbCellera Biologics
ABCL
151 hedge funds and large institutions have $909M invested in AbCellera Biologics in 2026 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 36 increasing their positions, 54 reducing their positions, and 26 closing their positions.
109% more capital invested
Capital invested by funds: $434M → $909M (+$475M)
50% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 26
33% more call options, than puts
Call options by funds: $42.5M | Put options by funds: $32M
9% more funds holding
Funds holding: 138 → 151 (+13)
2.98% less ownership
Funds ownership: 40.99% → 38.02% (-3%)
33% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$15.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$13.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.76M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$7.54M |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$6.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$17.2M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$15.9M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$11.4M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$10.1M |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$9.58M |
ABCL Hedge Fund Activity: Q2 2026 in Review
151 of the 8,303 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q2 2026, worth a combined $909M — up 109% from $434M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ABCL positions and 26 closed out — a net gain of 13 holders — while 36 added to existing stakes and 54 trimmed.
The largest buyer was Bank of America, adding an estimated $15.4M. The largest seller was Goldman Sachs, cutting an estimated $17.2M.
- 151 institutional investors held AbCellera Biologics (ABCL) as of Q2 2026, up from 138 in Q1 2026.
- Funds reported $909M of AbCellera Biologics stock for Q2 2026, up 109% quarter-over-quarter.
- 39 funds opened new AbCellera Biologics positions in Q2 2026 and 26 closed out, a net change of +13 holders.
- The largest AbCellera Biologics buyer in Q2 2026 was Bank of America, an estimated $15.4M added.
- The largest AbCellera Biologics seller in Q2 2026 was Goldman Sachs, an estimated $17.2M sold.
Based on aggregated 13F filings for Q2 2026.